Hematologic Cancers News
Duvelisib Delayed Progression in CLL/SLL: Study
Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.
Investigators Report the Successful Allogeneic Transfer of Cytotoxic T Lymphocytes in Progressive Multifocal Leukoencephalopathy
BK-virus-specific T cells from a third-party donor were shown to successfully clear a related virus known to cause PML in 3 patients with different conditions.
Dasatinib in Chronic Myeloid Leukemia Linked to Higher Healthcare Costs
Increased costs were found to be a result of more infections.
Fecal Transplantation Restores Patient Gut Microbiota Following Allo-HSCT
After antibiotic treatment during allogeneic hematopoietic stem cell transplantation, fecal transplantation was shown to restore patients' gut microbiota.
Pilot Study Supports Lower Dose of Ibrutinib in Chronic Lymphocytic Leukemia
In patients with chronic lymphocytic leukemia, a lower ibrutinib dose appears to confer sufficient biological activity, but further study is needed.
Multigene Panel Testing May Guide Diagnosis and Management of Hereditary Anemia
The overlapping phenotypes of many hereditary anemias can make differential diagnosis and classification very difficult,
Hemophilic Joint Bleeding Promotes Vascular Remodeling, Rebleeding Independent of Hemostatic Correction
Hemophilic joint bleeding often leads to aberrant expression of alpha-smoot muscle actin, which can indicate vascular remodeling.
Subcutaneous Emicizumab Effectively Prevents Bleeding in Patients With Hemophilia A
Emicizumab prophylaxis provides effective bleed prevention in people with hemophilia A with and without inhibitors.
Novel, von Willebrand factor-independent FVIII Therapy May Allow for Weekly Dosing
A novel, von Willebrand factor-independent factor VIII therapy may allow patients with severe hemophilia A to pursue weekly dosing.
Inhibitor Incidence Is Similar for Recombinant, Plasma-Derived FVIII Treatment Products
The study confirmed that recombinant and plasma-derived FVIII treatment products are associated with similar risk.
Philipp Tool Demonstrates Low Utility in Assessing Heavy Menstrual Bleeding for a Hemostatic Defect
Although anovulation is the most common cause of heavy menstrual bleeding, an underlying hemostatic defect may also contribute to this menstrual problem.
Leukemic Cells in CAR-T Find a New Way to Evade Immune Recognition
Standard flow cytometry missed the detection of the CAR19 epitope on the surface of the leukemia cells.
Whole-Body CT Influenced the Management of Myeloma and Precursor Diseases
The use of low-dose WBCT in multiple myeloma provided important information that helped guide patient management in 97% of the cases that were reviewed.
Rituximab Did Not Reduce Acute iTTP Relapses in Retrospective Observational Study
The use of rituximab for autoimmune thrombotic thrombocytopenic purpura did not significantly reduce acute iTTP relapses.
Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment
Results of the retrospective study require further confirmation.
Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.
Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML
For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Role of miR-125a-5p Clarified in Bladder Cancer
- Bladder Cancer Clinical Features Linked to EGFR and HER-2 Expression
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- A Vegan Diet and Cancer
- The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear